Rondes de santé : Un médicament expérimental double la survie des patientes atteintes d’un cancer de l’ovaire
February 13, 2026
Health rounds: Experimental drug doubles survival of ovarian cancer patients in trial| Reuters
February 13, 2026New hope for ovarian cancer, with Alexander Schneider
This article was originally published in Pharmaphorum
Behind every drug and drug candidate are stories – human stories as well as scientific stories. In this interview from the sidelines of the Biotech Showcase in San Francisco last month, Alexander Schneider, CEO of CureLab Oncology, shares both.
Speaking with pharmaphorum’s Jonah Comstock, he explains how his company’s drug candidate for platinum-resistant ovarian cancer is named after his wife Elena, a cancer survivor. He also tells the story of the serendipitous discoveries that led his team to develop what he hopes will be a game changer for women like Elena.
Check out the video below for the full story.
